Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0010200 (cough)
 23,843 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

1. We have assessed the effect of a specific histamine H1-receptor antagonist, terfenadine, in the treatment of atopic asthmatics during the grass pollen season. 2. Eighteen mild, grass pollen sensitive asthmatics (10F, 8M, mean +/- s.e. mean age 34.7 +/- 5.6 years), all of whom were controlled on inhaled beta 2-adrenoceptor agonists alone, took part in a 9 week, double-blind, crossover study using terfenadine 180 mg three times daily and placebo. Throughout the study patients recorded peak expiratory flow rate (PEFR) twice daily, symptoms of cough, wheeze, breathlessness and chest tightness (scored 0-3), and their use of bronchodilators. Methacholine inhalation challenge tests were performed each week. Data were analysed by a method suitable for a two group, two period crossover trial with baseline measurements. 3. Terfenadine significantly reduced symptoms of cough by 76.9% (P less than 0.05) and wheeze by 46.9% (P less than 0.02). Symptoms of breathlessness and chest tightness were reduced by 16.8 and 30.3% respectively but these were not statistically significant. Morning and evening PEFR rose by 5.5 (P less than 0.001) and 6.2% (P less than 0.003) respectively on treatment with terfenadine and bronchodilator use fell by 40.3%. A progressive increase in methacholine sensitivity was seen in both treatment groups throughout the study but did not reach statistical significance. 4. We conclude that treatment with terfenadine during the grass pollen season in sensitive asthmatics reduced their symptoms and bronchodilator requirements and produced a modest improvement in their lung function without affecting the development of increased methacholine sensitivity that occurred during the grass pollen season.
 ...
PMID:Terfenadine, a potent histamine H1-receptor antagonist in the treatment of grass pollen sensitive asthma. 197 43

Methacholine challenges were performed in ten subjects with mild asthma at 2 h before and 20 min after placebo or 5, 10, 20, 40, 80, and 160 mg of inhaled verapamil given in a single-blind randomized crossover manner on different days. While verapamil did not have a bronchodilator effect, the 10-mg dose modestly increased the concentration of methacholine required to decrease FEV1 by 20 percent (PC20). The mean (+/- SEM) increase in PC20 from baseline was 2.1 +/- 0.2 times baseline after 10 mg of verapamil, compared to 1.1 +/- 0.1 times baseline after placebo (p less than 0.001). Unexpectedly, bronchoconstriction (greater than 10 percent decrease in FEV1) associated with cough or wheezing was observed in seven of ten subjects at doses of 20 mg or more. This adverse effect was not related to the osmolarity of the nebulized solutions. Thirty minutes before a standardized exercise challenge, 13 subjects inhaled placebo, 10 mg, or the highest dose of verapamil tolerated during the methacholine study (20 to 160 mg) in a double-blind randomized crossover manner. The exercise challenge was aborted in three subjects because of bronchospasm that occurred after administration of the higher dose. The mean (+/- SEM) maximum change in FEV1 after exercise in the ten subjects completing all three regimens of treatment was -17.1 +/- 4.0 percent after placebo, -12.7 +/- 4.3 percent after 10 mg (p less than 0.05), and -6.4 +/- 3.6 percent after the highest dose (p less than 0.05). We conclude that increasing the dose of verapamil above 10 mg did not provide greater benefit but, paradoxically, induced bronchoconstriction in most of the subjects. Because of this potential bronchoconstrictor effect, high doses of oral or intravenous verapamil should be used with caution in asthmatic subjects.
 ...
PMID:Inhaled verapamil-induced bronchoconstriction in mild asthma. 206 Mar 39

We studied 68 chronic asthmatic patients, 18 to 76 yr of age, with a percent predicted FEV1 between 33 and 81, comparing cromolyn sodium with placebo. We used a double-blind, comparative group trial design. A 4-wk baseline period was followed by 3 months of active treatment or placebo. Patients recorded symptom severity and frequency of study drug and concomitant medication usage on daily diary cards. At each clinic visit, patients independently assessed the effectiveness of the test medication in controlling their asthma. Physicians also assessed the severity of the patients' symptoms, pulmonary function, and effectiveness of test medication at monthly intervals. Methacholine challenges were done pre- and post-treatment. Use of concomitant therapy was reduced according to a specified schedule. There was significant improvement in the severity of daytime asthma, nighttime asthma, and cough as assessed by the patients in the cromolyn sodium group. Mean use of concomitant medications decreased significantly in cromolyn sodium patients. Despite the reductions in the use of bronchodilators, pulmonary function (FEV1, FVC, FEF25-75) improved significantly in the cromolyn sodium group. Similar improvements did not occur in the control group. The physicians' assessments of symptoms showed significant improvement in favor of the cromolyn sodium group. Both physicians and patients judged cromolyn sodium to be moderately or very effective for 61% of the patients as compared to 27% (by physicians) and 24% (by patients) in the placebo group. There was no significant difference in methacholine response between the two groups, although the mean value for methacholine sensitivity in the cromolyn sodium group was significantly less at the end of the study than at baseline.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Cromolyn sodium is effective in adult chronic asthmatics. 249 60

To evaluate whether the potency of a long-acting selective beta 2-agonist negates the need for cromolyn, 27 children, aged 6 to 12 years, with mild to moderate asthma requiring long-term medication, were assessed for the therapeutic effects of cromolyn and/or terbutaline by jet nebulizer. Patients received either cromolyn, 20 mg, terbutaline, 0.1 mg/kg up to 4 mg, or the combination, three times daily. The study design was double-blind, crossover with each patient receiving the three treatment regimens in randomized order for a period of 8 weeks each. Daily diary mean scores generally demonstrated best symptom control with cromolyn or the combination than with terbutaline alone. Cough was significantly less with cromolyn than with terbutaline (p less than 0.05). Morning peak flow measures were higher with combination therapy than with terbutaline (p less than 0.05). Evening peak flow measures were higher with the combination and cromolyn alone than with terbutaline alone (p less than 0.01). Methacholine challenge demonstrated less bronchial hyperreactivity with the combination or cromolyn alone than with terbutaline alone (p less than 0.02). The effectiveness of the nebulizer regimen for children with chronic asthma is better when cromolyn is used alone or in combination with terbutaline than when the beta-agonist is used alone.
 ...
PMID:Double-blind evaluation of nebulized cromolyn, terbutaline, and the combination for childhood asthma. 312 40

The bronchoprovocation test has been widely used in diagnosis of bronchial asthma. Forty-eight cases under tentative diagnosis of bronchial asthma, with complaints of cough, shortness of breath, and wheezing, were studied by using histamine and methacholine. Their baseline pulmonary functions were all normal. Among the Fourteen cases, histamine and methacholine provocation tests were both negative in 14 cases (29%) (Group 1). There were 18 cases (37%) of allergic asthmatics with positive challenge to either histamine (2 cases) or methacholine (1 case) or both (15 cases) (Group 2). There were 16 cases (34%) of nonallergic asthmatics with positive challenge to either histamine (2 cases) or methacholine (3 cases) or both (11 cases) (Group 3). In Group 2, the average PD20 FEV1 for methacholine and histamine was 25.8 +/- 8.2 BU and 22.9 +/- 7.1 BU respectively; the average PD25 FEF25-75 for methacholine and histamine was 19.4 +/- 7.0 BU and 21.1 +/- 7.1 BU respectively. The sensitivities, compared between both agents, were nearly the same. In Group 3, the average PD20 FEV1 for methacholine and histamine was 35.1 +/- 9.0 BU and 54.5 +/- 9.6 BU respectively; the average PD25 FEF25-75 for methacholine and histamine was 27.9 +/- 8.6 BU and 50.2 +/- 9.6 BU respectively. Methacholine is more sensitive in detecting airway hyperreactivity in this group. When these two groups of asthmatics were compared, Group 2 patients were more sensitive to challenges with histamine and methacholine (p less than 0.02).(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Bronchoprovocation test in the normal and in asthmatics. 354 1

The prevalence of bronchial hyperreactivity to inhaled methacholine and of a clinical history of symptoms of asthma was determined in a birth cohort of 9 year old New Zealand children. A history of current or previous recurrent wheezing was obtained in 220 of 815 children. Of 800 who had spirometric tests, 27 (3.4%) had resting airflow obstruction (FEV1/FVC less than 75%). Methacholine challenge was undertaken without problem in 766 children, the abbreviated protocol being based on five breaths and four concentrations. A fall in FEV1 of more than 20% was observed in 176 children (23% of challenges, 22% of the full cohort) after inhalation of methacholine in concentrations of up to 25 mg/ml. The prevalence of bronchial reactivity in children with symptoms was related to the frequency of wheezing episodes in the last year, and the degree of reactivity to the interval since the last episode. Sixty four children (8.0%) with no history of wheeze or recurrent dry cough were, however, also responsive to methacholine 25 mg/ml or less, while 35% of children with current or previous wheezing did not respond to any dose of methacholine. Bronchial challenge by methacholine inhalation was not sufficiently sensitive or specific to be useful as a major criterion for the diagnosis of asthma in epidemiological studies. The occurrence of airway reactivity in children without symptoms of asthma, however, raises the possibility that adult onset asthma and the development of airways obstruction in some subjects with chronic bronchitis could have origins in childhood.
 ...
PMID:Prevalence of bronchial reactivity to inhaled methacholine in New Zealand children. 373 48

Ten patients, aged 7 to 16 years, were prospectively evaluated for chronic cough of more than 4 months duration. All patients denied wheezing, but in addition to cough complained of chronic obstructive nasal symptoms. Sinus roentgenograms were consistent with sinusitis in 7/10 patients. Methacholine bronchial provocation was positive in 6/9 patients. The patients were recalled for a 2-year follow-up evaluation. Of seven follow-up patients, bronchial asthma had developed in three, two patients had chronic cough and exercise-induced bronchospasm, and two patients had chronic cough without wheezing. Methacholine bronchial provocation was positive in 6/6 patients. Sinus roentgenograms were compatible with sinusitis in 4/7 patients. Chronic cough in some children may be a complaint of diffuse hyperreactive airways complicated by sinusitis. In some of the children the clinical course evolved into a diffuse respiratory tract disorder including chronic obstructive eosinophilic rhinitis, recurrent or chronic sinusitis and bronchial asthma. An IgE-mediated mechanism usually could not be shown in the pathogenesis.
 ...
PMID:Chronic cough, sinusitis, and hyperreactive airways in children: an often overlooked association. 397 34

Methacholine challenge for diagnosing hyperreactive airways has been valuable in both research and clinical care settings. There are two methods of challenge that are commonly used. With the dosimeter method, five breaths of sequential concentrations of methacholine are inhaled with use of a solenoid valve timing device to standardize the quantity of inhaled methacholine solution. Pulmonary function is assessed after each concentration is inhaled. With the continuous breathing method, each concentration of methacholine is inhaled by tidal volume breathing for 2 min. Pulmonary function is assessed after each concentration. With both methods, a fall in FEV1 of 20% after inhalation of methacholine is diagnostic of hyperreactive airways. Several evaluations demonstrate that pharmacologic bronchial provocation with methacholine is more sensitive than exercise challenge for making the diagnosis of hyperreactive airways. If the allergic athlete complains of exercise-related symptoms, such as cough, dyspnea, or chest pain, and an exercise tolerance test fails to reproduce these symptoms, a methacholine challenge should be performed before the possibility of exercise-induced asthma is dismissed. If the allergic athlete has symptoms of cough or dyspnea that are unrelated to exercise, methacholine challenge is the most sensitive method to evaluate airways hyperreactivity indicative of asthma.
 ...
PMID:Methacholine challenge--relevance for the allergic athlete. 637 Nov 5

Methacholine sensitivity was evaluated in 166 young subjects who had normal resting spirometric values but who presented problems suggesting lower airways hyperreactivity. Fifty-eight patients (35%) did not have significant sensitivity. The diagnosis of asthma was excluded in this subgroup. Forty-one patients (25%) had mild methacholine sensitivity, 49 (30%) had moderate sensitivity, and 18 (11%) had extreme methacholine sensitivity. Many patients who reacted had chief complaints of cough, bronchitis, or other low respiratory-tract symptoms and did not complain of wheezing. Methacholine challenge helped to clarify appropriate therapy in these individuals. One-year follow-up of these patients showed most patients to be continuing the therapeutic regimen that had been prescribed initially. Methacholine bronchoprovocation was a useful adjunct to management of this large outpatient population of children and young adults and deserves attention as a procedure relevant to patients care, not solely as an investigational test.
 ...
PMID:Methacholine bronchial challenge in children. 680 93

Methacholine challenge testing was performed in 20 patients with pulmonary sarcoidosis and 13 normal control subjects. Increased methacholine responsiveness was demonstrated in 10 of 20 patients with sarcoidosis. Sarcoidosis patients with increased reactivity differed from those with normal reactivity in that they had more airway obstruction, smaller vital capacities, and lower single breath diffusing capacities for carbon monoxide. Responders tended to be more symptomatic with wheezing and cough and to have a longer duration of disease, although these differences did not reach statistical significance.
 ...
PMID:Airway hyperreactivity in patients with sarcoidosis. 731 80


1 2 Next >>